Evercore ISI reiterates Boston Scientific stock rating on growth outlook
Evercore ISI has reiterated an Outperform rating for Boston Scientific (NYSE:BSX) with a $96.00 price target, based on expectations of sustained 9% revenue compound annual growth rate through 2028. The firm notes the stock is currently undervalued according to InvestingPro analysis and highlights the upcoming CHAMPION AF trial readout as a potential catalyst. Other analysts like Stifel, Truist Securities, Jefferies, and TD Cowen also maintain positive ratings, and the company recently strengthened its Board of Directors with new appointments.
https://m.investing.com/news/analyst-ratings/evercore-isi-reiterates-boston-scientific-stock-rating-on-growth-outlook-93CH-4577137?ampMode=1